Karyopharm Therapeutics (KPTI) Announces XPOVIO Data to be Presented at the European Hematology Association 2021 Virtual Congress

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that nine abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming European Hematology Association (EHA) 2021 Virtual Congress taking place June 9-17, 2021.

Key abstracts to be presented at the meeting will feature clinical data for XPOVIO® (selinexor), the Company's first in class, oral Selective Inhibitor of Nuclear Export (SINE) compound, including: (i) multiple new subgroup analyses from the pivotal Phase 3 BOSTON study, including data results evaluating XPOVIO treatment for patients over the age of 65 years old, patients with RAS-mutated multiple myeloma, patients previously treated with Revlimid® (lenalidomide), and genomic predictors of efficacy; (ii) updated data from the Kyprolis® (carfilzomib) and Pomalyst® (pomalidomide) arms of the Phase 1b/2 STOMP study evaluating XPOVIO in combination with standard of care agents in previously treated multiple myeloma; (iii) evaluation of XPOVIO combinations in patients with multiple myeloma following treatment with anti-CD38 monoclonal antibodies; (iv) the effect of lymphocyte count on safety and efficacy in the Phase 2b SADAL study evaluating XPOVIO in patients with diffuse large B-cell lymphoma; and (v) updated overall survival data from a Phase 1/2 study evaluating oral eltanexor, the Company's second generation SINE compound, in patients with hypomethylating-agent refractory myelodysplastic syndrome.

"We are pleased to see such a broad display of data from our clinical programs presented at EHA this year. In particular, we are encouraged that updated data from the Kyprolis® arm of the STOMP study was selected for an oral presentation," said Sharon Shacham, PhD, MBA, Chief Scientific Officer of Karyopharm. "More specifically, in the STOMP study, heavily pretreated multiple myeloma patients receiving once weekly XPOVIO in combination with once-weekly Kyprolis® and dexamethasone achieved an overall response rate of 78% (25/32 patients), including 16% (5/32 patients) who achieved a complete response. High response rates were observed whether or not the patients had received prior anti-CD38 monoclonal antibody therapy and adverse events in the study were generally consistent with other previously reported XPOVIO studies in multiple myeloma. We look forward to sharing these results and other XPOVIO data with the broader medical and scientific community."

Abstracts Featuring XPOVIO® (selinexor)

1. Title: Once Weekly Selinexor, Carfilzomib, and Dexamethasone (XKd) in Carfilzomib Nonrefractory Multiple Myeloma (MM) PatientsPresenter: Cristina Gasparetto, Duke University Cancer CenterAbstract #: S188Date and time: Friday, June 11, 2021; 3:00 a.m. ETSession type: Oral PresentationSession: New diagnostic and therapeutic approaches in multiple myeloma and AL amyloidosis
2. Title: Oral Selinexor, Pomalidomide, and Dexamethasone (XPd) at Recommended Phase 2 Dose in Relapsed Refractory Multiple Myeloma (MM) Presenter: Darrell White, QEII Health Sciences Center, Dalhousie UniversityAbstract #: EP-1008Date and time: Friday, June 11, 2021; 3:00 a.m. ETSession type: E-Poster PresentationSession: Myeloma and other monoclonal gammopathies – Clinical
3. Title: Selinexor Containing Regimens in Patients with Multiple Myeloma (MM) Previously Treated with anti-CD38 Monoclonal Antibodies Presenter: Cristina Gasparetto, Duke University Cancer CenterAbstract #: EP1002Date and time: Friday, June 11, 2021; 3:00 a.m. ETSession type: E-Poster PresentationSession: Myeloma and other monoclonal gammopathies – Clinical
4. Title: Survival Among Older Patients with Previously Treated Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd) in the BOSTON study Presenter: Thierry Facon, University HospitalAbstract #: EP976Date and time: Friday, June 11, 2021; 3:00 a.m. ETSession type: E-Poster PresentationSession: Myeloma and other monoclonal gammopathies – Clinical
5. Title: Effects of Selinexor on Previously Treated Multiple Myeloma (MM) with RAS-mutations Presenter: Christopher J. Walker, Karyopharm Therapeutics Inc.Abstract #: EP966Date and time: Friday, June 11, 2021; 3:00 a.m. ETSession type: E-Poster PresentationSession: Myeloma and other monoclonal gammopathies – Clinical
6. Title: Efficacy and Safety of Selinexor, Bortezomib, and Dexamethasone Based on Refractory Status to Lenalidomide in Patients with Previously Treated Multiple Myeloma: A Post-hoc Analysis of the BOSTON Study Presenter: Xavier Leleu, CHU de Poitiers, Hôpital La MileterieAbstract #: EP974Date and time: Friday, June 11, 2021; 3:00 a.m. ETSession type: E-Poster PresentationSession: Myeloma and other monoclonal gammopathies – Clinical
7. Title: Genomic Correlates of Response to Selinexor in Multiple Myeloma from the BOSTON Study Reveal a Predictive Signature Presenter: Paula Restrepo, Icahn School of Medicine at Mount SinaiAbstract #: EP936Date and time: Friday, June 11, 2021; 3:00 a.m. ETSession type: E-Poster PresentationSession: Myeloma and other monoclonal gammopathies - Biology & Translational Research
8. Title: Lymphocyte Count Effect on Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-hoc Analysis from Phase 2b SADAL Study Presenter: Michael Schuster, Stony Brook UniversityAbstract #: EP530Date and time: Friday, June 11, 2021; 3:00 a.m. ETSession type: E-Poster PresentationSession: Aggressive Non-Hodgkin lymphoma – Clinical Abstracts Featuring Eltanexor
9. Title: Updated Overall Survival of Eltanexor for the Treatment of Patients with Hypomethylating Agent Refractory Myelodysplastic SyndromePresenter: Sangmin Lee, Weill Cornell Medical CollegeAbstract #: EP924Date and time: Friday, June 11, 2021; 3:00 a.m. ETSession type: E-Poster PresentationSession: Myelodysplastic syndromes – Clinical

You May Also Be Interested In

• AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
• Neurocrine Biosciences (NBIX) Reports Positive Phase 2 Data for NBI-1065845
• Abeona Therapeutics (ABEO) Receives FDA Complete Response Letter on Pz-cel